---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-002602"
form_type: "8-K/A"
ticker: "BIXT"
cik: "0001445815"
company_name: "BIOXYTRAN, INC"
filed_at: "2025-04-03T23:59:59+00:00"
generated_at: "2026-05-23T22:26:34.499643+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bioxytran acquires NDPD Pharma in $15.85M stock deal; CFO adopts 10b5-1 plan

## Summary
- Acquired 100% of NDPD Pharma for 3,389,169 common shares and 28,467,564 preferred shares valued at ~$12.46M.
- NDPD held patents for PLM (PHGG) to treat COVID-19 and 60+ viruses; appraised asset value $15.85M including license.
- Related-party accounting (ASC 805-50) requires purchase price of $12.47M to be eliminated against equity, not recorded as assets.
- CFO Ola Soderquist adopted a 10b5-1 plan to sell up to 500,000 shares by Dec 31, 2025, contingent on price thresholds.
- NDPD was beneficially owned by company officers; transaction approved by board as a related-party acquisition.

## SEC filing metadata
- accession: 0001641172-25-002602
- form_type: 8-K/A
- ticker: BIXT
- cik: 0001445815
- company_name: BIOXYTRAN, INC
- filed_at: 2025-04-03T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1445815/000164117225002602/0001641172-25-002602-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1445815/000164117225002602/form8-ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-002602
- JSON: https://secwatch.observer/filing/0001641172-25-002602.json
- Plain text: https://secwatch.observer/filing/0001641172-25-002602.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.